Increasing initiatives for research and development for exploring novel cancer treatment methods are anticipated to provide growth opportunities for the global epigenetic market
Epigenetic is type of advanced scientific method used to study the factors that are changing the physical structure of DNA. For example, epigenetic change is DNA methylation. The epigenetic is proving highly beneficial to the cancer patients and their therapeutic development. Thus, the demand for advanced methods across the world for epigenetic applications is likely to rise in the years to come.
According to recent predictions, the global epigenetic market is expected to reach close to USD 36.45 billion until 2028 with an annualized growth rate of above 21.5.% from 2021 to 2028. The key factors supporting this optimistic growth spurt are increasing prevalence of various types of cancers coupled with high demand for advanced treatment methods including drugs, therapeutics, along with rising geriatric population, and increasing awareness of benefits of epigenetics in the field of cancer.
However, due to current limitations and challenges such as legal constraints, phenotypic variations in humans leading to cause of various diseases, expensive instruments for research and development, lack of suitable tissues required for studying the global epigenetic market may pinch down the optimistic growth rise.
On the contrary, supportive regulatory framework, subsidies provided on instruments, beneficial drugs and therapeutics are anticipated to be a growth opportunity for the global epigenetic market. In an effort to stay competitive the market players are upgrading their approaches and undertaking strategic initiatives with efficient products and services. They are introducing innovative solutions addressing the market demands thereby increasing their competitiveness in the global epigenetic testing market.
The Adroit Market Research Report gives a robust analysis of the global epigenetic market, a holistic overview of the competitive landscape, go-to market strategies with focus on vendor landscape, customer mapping, and the key market attributes of epigenetic inheritance, epigenetic testing and overall epigenetic market progress.
The global epigenetic market witnessed impressive growth post-pandemic and estimates a great market growth. The report best delivers the market information related to complex business models, overall market analysis with focus on opportunities and competitive landscape. The report assesses the market infrastructure, latest developments, distribution structure, and builds a profile database of the key companies.
The chip sequencing kits is expected to gather substantial market revenue in the forecasted years. The key factors such as high resolution and noise reduction over traditional kits, and permission cost for larger studies driving its market growth.
The next generation sequencers segment is gaining momentum in the market as it offers higher sensitivity in detecting variants with low frequency and has faster turnaround time, etc.
The antibodies segment accounted for largest market share because antibodies are the based on epigenetics is the biggest achievement in modern medicine and science. The antibodies developed on the basis of morbidity and mortality is reducing the bacterial infections and associated morbidity and mortality.
The DNA polymerases held the maximum market share and may record good market growth in the forthcoming years as it accurately replicates DNA sequences leading to increased demand in the market.
The increasing demand for efficient and advanced drugs, therapeutics, and methods addressing the solid and liquid tumors is increasing. And, tumors are the biggest area where epigenetics has advanced greatly. This is the key reason for the growth of solid and liquid tumour segment in the market.
North America is the largest contributor to the global epigenetic market. Thy key factors such as presence of prominent research institutions in the region, significant pharma and bitotech firms, high disposable incomes, and rising adoption of advanced methods to address the rising prevalence of fatal disease like cancer are driving the growth of the market.
Asia Pacific is also a major contributor to the growth of global epigenetic market due to increasing awareness of adopting advanced methods, supportive government policies increasing investments, etc.
The leading firms in the global epigenetic market are Abcam, Active Motiff, Illumina, Merck & Co, and Diagenode among all other established and emerging players.
Key Segments of the Global Epigenetic Market
Kit Type Overview, 2018-2028 (USD Billion)
- Chip Sequencing Kits
- Bisulfite Conversion Kits
- Whole Genome Amplification Kits
- 5-hmC & 5-mC Analysis Kits
- RNA Sequencing Kits
Reagents Type Overview, 2018-2028 (USD Billion)
- Antibodies
- Magnetic Beads
- Histones
- Buffers
- Primers
Enzymes Type Overview, 2018-2028 (USD Billion)
- DNA Polymerases
- Other DNA-Modifying Enzymes
- DNA Ligases
- Methyltransferases
- Acetylases
- Reverse Transcriptase
- Other Protein-Modifying Enzymes
- RNA Ligases
Instruments Type Overview, 2018-2028 (USD Billion)
- Next generation Sequencers
- qPCRs
- Mass Spectrometers
- Sonicators
Application Overview, 2018-2028 (USD Billion)
- Solid Tumors
- Liquid Tumors
- Non-oncology
- Metabolic diseases
- Infectious diseases
- Inflammatory diseases
- Cardiovascular diseases
Regional Overview, 2018-2028 (USD Billion)
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East and Africa